arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Coherus Oncology, Inc.

CHRS
$0.75 ▼ -0.11 (-12.29%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
15 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
39
Health
Weak
Neutral
auto_awesome

Analytical Summary

Coherus Oncology, Inc. shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $87.9M
Dividend Yield —
Revenue Growth 59.8% ↗
Op. Margin -429.5%
ROIC -296.9% ↘
FCF / Share $-1.18 ↘
Trailing P/E 0.5x
Price / Book 1.5x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

15-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$42.17M
↑ +59.8% —
Net Income Profit after all expenses
$168.02M
↑ +489.4% —
Operating Margin Operating profit as % of sales
-429.5%
↓ -443.8% 0th
FCF / Share Free cash flow per share
$-1.18
↓ -562.7% —
trending_up

Bullish Indicators

  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↓
0
Returns
100
Financial Health ↓
24
Cash Quality
11

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 15 years · 55 quarters